Novo Nordisk, FDA

Shortage of Novo's Wegovy and Ozempic is resolved, FDA website shows
A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, the U.S. Food and Drug Administration's website showed on Friday. The resol
Novo’s Ozempic, Wegovy Shortage Ends, Threatening Copycats
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s expected to curtail widespread access to cheaper copies of the popular medications.
FDA declares Wegovy and Ozempic shortage over, Novo Nordisk confirms
Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration has determined the shortage of Wegovy and Ozempic is resolved. “The
Novo Nordisk shortage of Ozempic and Wegovy ends, threatening compounders
The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for compounding pharmacies to make copies of Ozempic and Wegovy.
US FDA Says Shortage of Novo's Weight-Loss Drug Resolved
(Reuters) - A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, the U.S. Food and Drug Administration's website showed on Friday. The resolution comes two months after the health regulator said there was no longer a shortage of Eli Lilly's weight-loss and diabetes drugs.
FDA declares Wegovy® and Ozempic® shortage is over and that Novo Nordisk is fully meeting or exceeding nationwide demand for all doses
Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has determined the shortage of Wegovy® and Ozempic® is resolved. The FDA's assessment confirms the U.S. supply of these prescription-only GLP-1 medicines now meets or exceeds both current and projected U.
Novo Nordisk up 6%, Hims & Hers down 15% as FDA says Ozempic shortage over
Shares of Novo Nordisk (NVO) are up 6% in pre-market trading after a FDA drug shortage notice indicated that a shortage of several versions of
U.S. attorneys general forum urges FDA to act against counterfeit weight loss drugs
A bipartisan group of U.S. state and territory attorneys general is pressing the FDA to take prompt action against those threatening public health by marketing counterfeit forms of branded weight loss medications developed by Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY).
Dozens of attorneys general urge FDA to crack down on counterfeit obesity drugs
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
Novo Nordisk alleges fraud after $1.3 billion deal to buy hypertension drug from KBP Biosciences
Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...
Hotdogs and motorways: The ripples created by Denmark's Ozempic and Wegovy boom
American demand for weight-loss drugs is supercharging Denmark’s economy and transforming a small Danish community into an ...
Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.
Why Novo Nordisk Stock Keeps Going Down
Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...
Novo Nordisk stock is having a rough week after that Hims & Hers Super Bowl ad
Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...